Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$1.58 -6.0%	$2.10	$1.55 ▼ $17.31	$38.49M	N/A	170,906 shs	420,073 shs
BETRF BetterLife Pharma	$0.07 +10.0%	$0.07	$0.05 ▼ $0.15	$9.65M	1.52	32,900 shs	21,000 shs
CLNN Clene	$4.28 -2.1%	$3.24	$2.28 ▼ $8.00	$38.43M	0.49	89,466 shs	64,162 shs
KPTI Karyopharm Therapeutics	$4.38 -1.4%	$5.12	$3.51 ▼ $17.40	$37.84M	0.23	81,693 shs	23,673 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	0.00%	-20.20%	-18.97%	-59.59%	+157,999,900.00%
BETRF BetterLife Pharma	0.00%	+12.88%	-8.02%	+13.05%	-17.77%
CLNN Clene	0.00%	+4.39%	+80.59%	+9.18%	-46.00%
KPTI Karyopharm Therapeutics	0.00%	-0.23%	-4.58%	-32.72%	-70.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARTV Artiva Biotherapeutics	2.6127 of 5 stars	3.5	0.0	0.0	0.0	2.1	1.7	1.3
BETRF BetterLife Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CLNN Clene	2.4607 of 5 stars	3.6	3.0	0.0	0.0	0.6	2.5	0.6
KPTI Karyopharm Therapeutics	3.6993 of 5 stars	3.5	1.0	0.0	4.6	0.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTV Artiva Biotherapeutics	3.00	Buy	$17.80	1,026.58% Upside
BETRF BetterLife Pharma	0.00	N/A	N/A	N/A
CLNN Clene	3.17	Buy	$40.00	834.58% Upside
KPTI Karyopharm Therapeutics	3.00	Buy	$43.20	886.30% Upside

Current Analyst Ratings Breakdown

Latest BETRF, ARTV, CLNN, and KPTI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	ARTV Artiva Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$12.00
5/15/2025	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $18.00
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00
5/13/2025	KPTI Karyopharm Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
5/13/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $42.00
5/8/2025	CLNN Clene	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$84.00 ➝ $33.00
5/8/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/23/2025	CLNN Clene	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
4/8/2025	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/8/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/8/2025	CLNN Clene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTV Artiva Biotherapeutics	$250K	153.96	N/A	N/A	$7.68 per share	0.21
BETRF BetterLife Pharma	N/A	N/A	N/A	N/A	($0.04) per share	N/A
CLNN Clene	$340K	113.04	N/A	N/A	($1.06) per share	-4.04
KPTI Karyopharm Therapeutics	$145.24M	0.26	N/A	N/A	($22.10) per share	-0.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTV Artiva Biotherapeutics	-$65.37M	N/A	0.00	N/A	N/A	N/A	-75.95%	-39.51%	6/23/2025 (Estimated)
BETRF BetterLife Pharma	-$2.55M	-$0.02	N/A	∞	N/A	N/A	N/A	-1,124.01%	6/25/2025 (Estimated)
CLNN Clene	-$39.40M	-$4.04	N/A	N/A	N/A	-8,306.00%	-1,106.30%	-105.11%	8/6/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$76.42M	-$13.26	N/A	N/A	N/A	-43.99%	N/A	-35.95%	8/5/2025 (Estimated)

Latest BETRF, ARTV, CLNN, and KPTI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million
5/8/2025	Q1 2025	ARTV Artiva Biotherapeutics	-$0.68	-$0.83	-$0.15	-$0.83	N/A	N/A
5/7/2025	Q1 2025	CLNN Clene	-$1.10	-$0.50	+$0.60	-$0.09	$0.07 million	$0.08 million
3/24/2025	Q4 2024	CLNN Clene	-$1.21	-$1.67	-$0.46	-$1.67	$0.13 million	$0.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
BETRF BetterLife Pharma	N/A	N/A	N/A	N/A	N/A
CLNN Clene	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTV Artiva Biotherapeutics	N/A	13.93	13.93
BETRF BetterLife Pharma	N/A	0.03	0.03
CLNN Clene	N/A	1.36	1.36
KPTI Karyopharm Therapeutics	N/A	1.33	1.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTV Artiva Biotherapeutics	N/A
BETRF BetterLife Pharma	0.01%
CLNN Clene	23.28%
KPTI Karyopharm Therapeutics	66.44%

Insider Ownership

Company	Insider Ownership
ARTV Artiva Biotherapeutics	21.40%
BETRF BetterLife Pharma	34.77%
CLNN Clene	35.30%
KPTI Karyopharm Therapeutics	2.75%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTV Artiva Biotherapeutics	81	24.36 million	19.15 million	N/A
BETRF BetterLife Pharma	7	129.46 million	84.45 million	Not Optionable
CLNN Clene	100	8.98 million	5.81 million	Optionable
KPTI Karyopharm Therapeutics	380	8.64 million	8.40 million	Optionable

BETRF, ARTV, CLNN, and KPTI Headlines

Recent News About These Companies

Karyopharm to Present at the Jefferies Global Healthcare Conference

June 3, 2025 | prnewswire.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | prnewswire.com

Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now

May 26, 2025 | zacks.com

Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?

May 19, 2025 | zacks.com

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

May 19, 2025 | prnewswire.com

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

May 14, 2025 | prnewswire.com

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates

May 12, 2025 | zacks.com

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

May 12, 2025 | prnewswire.com

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

May 8, 2025 | prnewswire.com

Why Karyopharm Therapeutics Inc.’s (KPTI) Stock Is Down 5.15%

May 6, 2025 | aaii.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2025 | prnewswire.com

Karyopharm Therapeutics Inc.DL-Exch. Notes 2018(25) Bond

May 1, 2025 | markets.businessinsider.com

Why Karyopharm Therapeutics Inc.’s (KPTI) Stock Is Up 5.06%

April 30, 2025 | aaii.com

Karyopharm Therapeutics Inc. Common Stock (KPTI)

April 23, 2025 | nasdaq.com

Karyopharm Therapeutics Inc. Common Stock (KPTI)

April 23, 2025 | nasdaq.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 1, 2025 | prnewswire.com

Karyopharm price target lowered to split-adjusted $15 from $75 at Piper Sandler

March 20, 2025 | markets.businessinsider.com

Karyopharm Therapeutics (KPTI) Receives a Buy from Piper Sandler

March 20, 2025 | markets.businessinsider.com

Why Karyopharm Therapeutics Inc.’s (KPTI) Stock Is Up 10.77%

March 8, 2025 | aaii.com

Why Karyopharm Therapeutics Inc.’s (KPTI) Stock Is Down 12.14%

March 5, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BETRF, ARTV, CLNN, and KPTI Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

$1.58 -0.10 (-5.95%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.63 +0.05 (+3.16%)

As of 06/20/2025 07:43 PM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

BetterLife Pharma OTCMKTS:BETRF

$0.07 +0.01 (+10.04%)

As of 06/20/2025 09:30 AM Eastern

BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

Clene NASDAQ:CLNN

$4.28 -0.09 (-2.06%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$4.28 0.00 (0.00%)

As of 06/20/2025 05:55 PM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Karyopharm Therapeutics NASDAQ:KPTI

$4.38 -0.06 (-1.35%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$4.42 +0.04 (+1.03%)

As of 06/20/2025 04:04 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time